Sanofi-Aventis receives expanded Lovenox approval
During this kind of heart attack, known as acute ST-segment elevation myocardial infarction (STEMI), an artery is generally completely blocked by a blood clot for long enough to
Summit Therapeutics’ partner Akeso has secured China’s National Medical Products Administration (NMPA) authorisation for the use of ivonescimab in combination with chemotherapy as a first-line treatment for advanced squamous non-small cell lung cancer (NSCLC) patients.